The Asian Health Foundation announces a free toolkit for HCPs treating liver disease in AAPI populations

The Asian Health Foundation announces a free toolkit for HCPs treating liver disease in AAPI populations

I'll B There: Hepatitis B in Our Community

Request your free toolkit

Produced by the Asian Health Foundation, and supported by an independent educational grant from Gilead Sciences, Inc.

AAPIs comprise ~50% of CHB cases, but only comprise 6% of the population in the U.S.

Chronic hepatitis B virus (CHB) is often called a “silent killer” because people may have no symptoms and are unaware that they are infected, over many years, until developing serious liver disease, liver failure, or liver cancer.

In the United States, Asian Americans and Pacific Islanders (AAPIs) are disproportionately impacted by CHB, with approximately half of the cases while comprising only 6% of the population. CHB is the leading cause of liver cancer for Asian Americans. In addition, delays in identifying disease status can result in an increased probability of virus transmission to others, limited treatment options, and poorer patient outcomes.

Although there is currently no cure, vaccines for preventing hepatitis B and effective treatments for patients who have hepatitis B are available.

However, there is an alarmingly low level of understanding and knowledge of hepatitis B in the AAPI population and healthcare provider community.

This activity is supported by an independent educational grant from Gilead Sciences, Inc.